الصفحة الرئيسية>>Signaling Pathways>> Ubiquitination/ Proteasome>> ULK>>MRT68921 dihydrochloride

MRT68921 dihydrochloride

رقم الكتالوجGC36654

ثنائي هيدروكلوريد MRT68921 هو مثبط قوي لـ ULK1 و ULK2 ، بقيم IC50 تبلغ 2.9 نانومتر و 1.1 نانومتر ، على التوالي

Products are for research use only. Not for human use. We do not sell to patients.

MRT68921 dihydrochloride التركيب الكيميائي

Cas No.: 2080306-21-2

الحجم السعر المخزون الكميّة
5mg
56٫00
متوفر
10mM (in 1mL Water)
61٫00
متوفر
25mg
204٫00
متوفر
50mg
362٫00
متوفر
100mg
501٫00
متوفر
200mg
844٫00
متوفر

Tel:(909) 407-4943 Email: sales@glpbio.com

مراجعات العميل

بناء على آراء العملاء.

  • GlpBio Citations

    GlpBio Citations
  • Bioactive Compounds Premium Provider

    Bioactive Compounds Premium Provider

Sample solution is provided at 25 µL, 10mM.

Description Protocol Chemical Properties Product Documents Related Products

MRT68921 dihydrochloride is the most potent inhibitor of ULK1 and ULK2, with IC50 values of 2.9 nM and 1.1 nM, respectively.

ULK1, a serine/threonine protein kinase, is essential for the initial stages of autophagy. MRT68921 inhibits ULK1 and ULK2 in vitro and block autophagy in cells. MRT68921 is the most potent inhibitor of both ULK1 and ULK2, with greater than a 15-fold reduction in the IC50 for ULK1 (2.9 nm) and greater than a 30-fold reduction for ULK2 (1.1 nm). Autophagy-inhibiting capacity of the compounds is specifically through ULK1. ULK1 inhibition results in accumulation of stalled early autophagosomal structures, indicating a role for ULK1 in the maturation of autophagosomes as well as initiation[1].

[1]. Petherick KJ, et al. Pharmacological inhibition of ULK1 kinase blocks mammalian target of rapamycin (mTOR)-dependent autophagy. J Biol Chem. 2015 May 1;290(18):11376-83.

مراجعات

Review for MRT68921 dihydrochloride

Average Rating: 5 ★★★★★ (Based on Reviews and 19 reference(s) in Google Scholar.)

5 Star
100%
4 Star
0%
3 Star
0%
2 Star
0%
1 Star
0%
Review for MRT68921 dihydrochloride

GLPBIO products are for RESEARCH USE ONLY. Please make sure your review or question is research based.

Required fields are marked with *

You may receive emails regarding this submission. Any emails will include the ability to opt-out of future communications.